$9.94
-0.42-4.05%
In chiusura: Nov 16, 4:00 PM EST
$9.82
-0.12-1.23%
Post-mercato: 5:53 PM EST

The average analyst price target for Climb Bio is $25.29, 157.6% above the current price. Of 15 analysts, 15 rate it Buy. Targets range from $9 to $35. The latest change came on Nov 6, 2026, when Wedbush raised its price target on Climb Bio from $25 to $27 and kept an Outperform rating.
Price Target Range — 7 Quarters
Analyst Consensus — 15 Analysts
Rating Trend — Last 9 Months